@entity157 ( @entity157 ) is a major health concern, and early @entity157 diagnosis is a primary radiological concern. The goal of imaging @entity1575 is the early identification of high-grade @entity6349 nodules/early @entity157 since their treatment is associated with a higher chance of radical cure and lower recurrence rates. The newly introduced MRI contrast agent @entity18497 ( @entity18497 , @entity18497 ) has enabled the concurrent assessment of @entity5 vascularity and hepatocyte-specific contrast enhancement during the @entity2763 ( @entity2763 ), which can help to detect and characterize smaller HCCs and their precursors. @entity2763 -EOB-MRI identifies hypovascular @entity157 nodules that are difficult to detect using ultrasonography or computed tomography, which do not show the diagnostic @entity157 hallmarks of arterial washin and portal/delayed washout. During the @entity2763 , typical @entity157 and early @entity157 appear hypointense on EOB-MRI, whereas low-grade @entity6349 or regenerative nodules appear as iso- or hyperintense lesions. The diagnostic accuracy of EOB-MRI for the diagnosis of early @entity157 is approximately 95-100%. One third of hypovascular hypointense nodules in @entity2763 become hypervascular 'progressed' @entity157 , with a 1- and 3-year cumulative incidence of 25 and 41%, respectively. Therefore, these hypovascular nodules should be strictly followed up or definitely treated as typical @entity157 . Due to this capability of identifying the precursors and biological behavior of @entity157 , EOB-MRI has rapidly become a key imaging tool for the diagnosis of @entity157 and its precursors, despite the scarce MRI availability throughout Europe. With increasing experience, EOB-MRI may eventually be established as the diagnostic imaging modality of choice in this setting. Full recognition by the Western EASL-AASLD guidelines is expected.

Focal lesions in the cirrhotic liver: their pivotal role in XXXX -enhanced MRI and recognition by the Western guidelines.

@entity18497 :: ('MESH:C073590', 'Chemical') :: ['gadoxetic acid', 'Gd-EOB-DTPA', 'gadolinium-ethoxybenzyl-diethylenetriamine pentaacetic acid'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity2763 :: ('MESH:D000210', 'Disease') :: ['HBP', 'hepatobiliary phase'] @entity1575 :: ('MESH:D008103', 'Disease') :: ['liver cirrhosis'] @entity157 :: ('MESH:D006528', 'Disease') :: ['HCC', 'Hepatocellular carcinoma'] @entity6349 :: ('MESH:D004416', 'Disease') :: ['dysplastic']
@entity18497 :: (MESH:C073590,Chemical) :: ['gadoxetic acid']
